Waycross Partners’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
Other funds holding LLY
Waycross Partners's LLY Position: Q1 2026 in Review
Waycross Partners sold out of Eli Lilly (LLY) in Q1 2026, closing a stake of 4,000 shares — an estimated $4.3M sold.
Waycross Partners first reported a position in LLY in Q1 2021 and held it in 20 quarters. The position peaked at $12.2M in Q1 2023. 4,379 funds tracked by Wall St. Rank hold LLY as of Q1 2026.
- Waycross Partners reported no remaining Eli Lilly position as of Q1 2026 after selling out during the quarter.
- Waycross Partners sold 4,000 Eli Lilly shares in Q1 2026, an estimated $4.3M.
- Waycross Partners first reported a position in Eli Lilly in Q1 2021 and held it in 20 quarters.
- Waycross Partners's Eli Lilly position peaked at $12.2M in Q1 2023.
- 4,379 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.
Based on Waycross Partners's 13F filing for Q1 2026, filed 7 May 2026.